| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
|
|
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C22H25N3O2S |
| Molar mass | 395.52 g/mol |
S-14671 is a naphthylpiperazine derivative which acts as a 5-HT1A receptor agonist (pKi = 9.3) with high efficacy and exceptional in vivo potency, and also as a 5-HT2A and 5-HT2C receptor antagonist (both are pKi = 7.8). It displays only low and non-significant affinity for 5-HT1B and 5-HT3 sites.
In producing 5-HT1A-mediated effects such as hypothermia and spontaneous tail flicks in rodents, S-14671 is active at doses as low as 5 µg subcutaneously, and is about 10-fold more potent than 8-OH-DPAT and 100-fold more potent than flesinoxan and buspirone. Other 5-HT1A-mediated effects of S-14671 include induction of flat-body posture, corticosterone secretion, inhibition of morphine-induced antinociception, and attenuation of the electrical activity of the dorsal raphe nucleus.